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Summary Antibody targeted therapy of cancer results in anti-antibody production which prevents repeated
treatment. Cyclosporin A (CsA) has been used to suppress this response in patients treated with a
radiolabelled antibody to carcinoembryonic antigen (CEA). Patients with CEA producing tumours received a
minimum of two courses consisting of an injection of radiolabelled antibody and CsA, 24 mgkg-1 day-1, for
6 days; each course was given at 2 week intervals. Two weeks after the completion of the second course the
mean human antimouse antibody (HAMA) levels were 3.5 ugml-1 (s.d. 2.7) in 3 patients receiving CsA and
1,998 pgml- 1 (s.d. 387) in 3 patients not receiving the drug. Clearance of antitumour antibody was
accelerated and tumour localisation absent when HAMA levels exceeded 30pgml-1. With lower levels of
HAMA in the CsA-treated patients, further antitumour antibody accumulated in the tumour after each dose.
Further therapy with antitumour antibody and CsA lead to the development of HAMA, but this was less
than 25% of the amount in patients not given CsA. In this preliminary study up to 4 times as many doses of
antitumour antibody could be usefully given when CsA was used. This increases the potential for effective
antibody targeted therapy of cancer.
Therapy of cancer with intravenous antitumour mouse
monoclonal antibodies alone or conjugated to radionuclides
or toxins has produced tumour responses but these are
seldom sustained (Meeker et al., 1985, Order et al., 1985,
Lenhard et al., 1985, Spitler et al., 1987). Repeated therapy
would probably be more effective but is prevented by the
formation of human antimouse antibody (HAMA) after one
or more injections of antitumour antibody (Meeker et al.,
1985, Carrasquillo et al., 1984, Shawler et al., 1985). This
causes hypersensitivity reactions and prevents antitumour
antibody from localising in the tumour.
CsA is a powerful inhibitor of humoral immunity (Borel et
al., 1976) and has recently been shown in the accompanying
paper to prevent the antibody response to repeated injections
of mouse monoclonal antibodies in rabbits (Ledermann et
al., 1988). The suppression of the anti-antibody response is
likely to benefit those patients treated with repeated injec-
tions of antibody targeted therapy when the cytotoxic action
of the conjugate does not depend on host natural effector
mechanisms which may be perturbed by the complex actions
of CsA on the immune system. This study investigates the
effect of CsA on the formation of HAMA in patients with
CEA-producing tumours treated with repeated doses of a
131-iodine (131I)-labelled mouse monoclonal antibody to
CEA.
Patients and methods
Patients
Six patients with CEA-producing tumours and performance
status 0-2 (WHO Handbook, 1979) were investigated. All
had locally recurrent or metastatic tumour and conventional
therapy had failed. HAMA levels were below 5Mgml-.
Details of individual patients are given in Table I.
Methods
Mouse monoclonal IgG1 antibody to CEA (A5B7)
(Harwood et al., 1986) was produced in supernatant culture
and protein A purified. Before radiolabelling with 1311 by
the chloramine T method, A5B7 was centrifuged at 48,000g
for 2h as previously described (Ledermann et al., 1988).
After negative intradermal testing with 10,pg antibody, the
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thyroid was blocked with oral potassium iodide, 180mg 8
hourly for 14 days and potassium perchlorate, 200mg 6
hourly for 4 days. CsA 24mgkg1day'-, divided in three
oral doses was given for 6 days. Forty-eight hours after
starting CsA 5-7.5mg of antibody labelled with 40-80mCi
1311 (1311-A5B7) was infused intravenously in 20min by
displacement from a lead shielded container by isotonic
saline. The course of CsA and antibody was repeated every
14 days for up to 4 courses. Blood CsA levels were measured
by radioimmunoassay (Dr D. Holt, Guys Hospital, London).
The dose of CsA was adjusted to maintain blood levels
between 1,000 and 1,500ngml-1 and to prevent a progress-
ive rise in serum creatinine levels. Samples for HAMA were
measured before therapy and at intervals after each dose.
The distribution of radioactivity in the normal tissues and
tumour was determined by planar and single photon emis-
sion tomography (SPET) imaging using an IGE Gemini
gamma camera.
HAMA levels were measured by enzyme immunoassay.
Dilutions of serum in PBS containing 0.05% Tween and
0.1% bovine serum albumin were incubated for 2h at room
temperature in microtitre wells coated with 10pgml-l A5B7
in carbonate-bicarbonate buffer, pH9.6. After washing, wells
were incubated with goat anti-human IgG conjugated to
alkaline phosphatase (Sigma) followed by the addition of p-
nitrophenyl phosphate. The absorbance was recorded on a
Titertek Multiskan. The assay was standardised using
HAMA immunopurified on an A5B7-Sepharose-CL4B
column.
Anti-idiotypic antibody was measured by inhibition of
binding of HAMA to A5B7, as above, after serum, contain-
ing 150ngml-1 of human IgG anti-mouse antibody was
incubated at room temperature overnight with 1,000pgml-1
of either A5B7 or SB1O. The latter is a mouse monoclonal
antibody of the same isotype directed against human chorio-
nic gonadotrophin and does not react with CEA.
Toxicity and response were characterised using WHO
criteria (WHO Handbook, 1979).
Results
HAMA formation
Three patients received 1311-A5B7 with CsA and three
without. Details of the patients are shown in Table I. Two
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Table I Patients details.
Serum Prior
No. Diagnosis Age Sex CEA(pg1-) therapy CsA
1 Carcinoma of the colon 66 M 89 Pelvic irradiation No
2 Bronchial oat cell 76 F 35 Spinal irradiation, No
carcinoma combination chemotherapy
3 Carcinoma of the rectum 73 F 141 Pelvic irradiation, No
combination chemotherapy
4 Carcinoma of stomach 60 M 566 Mediastinal irradiation, Yes
combination chemotherapy
5 Carcinoma of the colon 49 F 94 Combination chemotherapy Yes
6 Carcinoma of the rectum 43 M 622 Combination chemotherapy Yes
doses of 131I-A5B7 were given to all patients and treatment
was repeated for up to four doses if HAMA values remained
below 6pgml-1 and the patient was well enough. In patients
receiving CsA, HAMA levels were not significantly changed
from the pre-treatment values 14 days after the second dose
(mean, 3.5 pgml -1 s.d. 2.7). The patients not given CsA
showed a rise in HAMA values after the first dose of 13I_
A5B7 and this continued reaching a mean of 1,998pgml-1
(s.d. 387) 14 days after the second dose (Figure 1). Two of
the CsA-treated patients continued treatment, one receiving
3 and another 4 courses of 131I-A5B7 with CsA. HAMA
levels rose 2 weeks after the third and fourth courses
respectively. Maximum levels were <25% of the HAMA
concentrations detected in patients treated without CsA
(Figure 1). The patients not receiving CsA stopped treatment
after 2 courses because of raised HAMA levels.
Anti-idiotypic antibody could be detected in all patients at
some time during therapy. It accounted for a median of
32.5% of the HAMA response and the quantity tended to
increase with successive therapy (Figure 2). No difference in
the pattern of the IgG response to the constant and variable
region of the A5B7 molecule was seen in the patients who
received CsA and those given radiolabelled antitumour anti-
body alone. When HAMA production was suppressed by
CsA so too was antiidiotype.
Clearance of 131I-ASB7 and tumour localisation
Patients with HAMA below 6pgml -1 at the start of a
course of treatment showed a similar rate of clearance of
131I-A5B7 with each course (Figure 3a). One patient had an
increase in HAMA to 39pgml-1 before the second dose and
showed more rapid clearance (Figure 3b).
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Figure 1 Human antimouse antibody (HAMA) levels in
patients with ( ) and without (- - -) CsA. Therapy
with '311-A5B7 is shown by arrows. The patients indicated by 0
had 3 and * 4 doses of 1311-A5B7.
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Figure 2 The human IgG anti-mouse response to constant and
variable (idiotypic) regions of A5B7. The inhibition of binding of
HAMA to A5B7 in the presence of blocking with O A5B7 or E
SB1O, both IgG1 antibodies, is expressed as a percentage of the
binding of HAMA in the absence of blocking antibodies.
Serial gamma camera images showed that when HAMA
levels were below 6pgml-1, repeated therapy led to further
accumulation of radioactivity in the tumour with each dose.
There was no difference in the general distribution
(Figure 4). The patient in Figure 3b whose HAMA levels
rose to 39pgml-1 before the second dose of 131I-A5B7
showed no tumour localisation although this had been good
with the first dose when the HAMA level was 1 gml-1.
This was associated with rapid clearance of 1311-A5B7 in the
presence of HAMA (Figure 5). There was pain relief and a
fall in serum CEA levels after the first dose but none after
the second.
Toxicity
The patient who had a second injection of 131I-A5B7 in the
presence of HAMA values of 39pgml1 developed an
allergic reaction 6min after the start of antibody infusion
with flushing, faintness, epigastric pain and vomiting. It
resolved rapidly after injection of chlorpheniramine and
hydrocortisone. One patient had a rigor lasting 30 minutes
after antibody administration. Patients receiving CsA had
nausea and anorexia lasting for the duration of CsA
administration (2 WHO grade I and 1 grade III). Two had
headaches and 1 had grade I renal impairment. Myelo-
suppression, attributed to radiation by 1311 occurred in
patients previously given chemotherapy or radiotherapy
regardless of whether CsA was administered. Two patients
had grade IV and 2 grade II thrombocytopaenia; one had
leucopaenia of grade II and 1 of grade IV. One patient had
anaemia, grade I. Nadirs were from 4 to 15 weeks after the
first therapy.656 J.A. LEDERMANN et al.
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Figure 3 Clearance of 131I-A5B7 from the circulation in the absence and presence of human
patients with levels of HAMA below 6pgml-1 before each dose of 1311-A5B7. One had 3 doses (-
). (b) A patient with HAMA below 6jigml-l before the first dose ( ) and 39pgml-
antimouse antibody. (a) Two
-) and the other 4 doses
I before the second (
Survival and response
There was no difference in survival attributable to the use of
CsA. Of those given CsA two died of tumour after 53 and
172 days and one survives at 276 days. Of those not having
CsA 2 died of tumour after 51 and 100 days and I survives
after 312 days. There were symptomatic improvements in 2
patients and falls in serum CEA levels in 3 but no partial or
complete remissions by WHO criteria.
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Figure 4 Repeated tumour localisation in the absence of
HAMA. (a) Anterior images of the trunk show localisation of
1311 in liver metastases (arrows) 220h after the first dose of 1311_
A5B7. (b) Good tumour localisation occurred again 213 h after
the third dose when HAMA was still absent. The thyroid gland
(T) also contains some 131.
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Figure 5 Accelerated clearance when HAMA was produced
after the first dose of 1311-A5B7. (a) Anterior imaging of the
trunk 6 h after the first dose shows 1311 in the heart (H) and
vascular areas. Free 1311 is in the bladder (B). (b) On anterior
imaging 3 h after the second dose, antibody has cleared from the
circulation into the liver (L).
Discussion
Immunogenicity is a potential problem in the therapeutic use
of macromolecular products of biotechnology which can
prevent their repeated administration. This paper shows that
CsA permits repeated therapy with antitumour monoclonal
antibodies by suppressing HAMA formation in patients.
More antibody accumulates in the tumour with each dose
and up to 4 times as many doses could usefully be given
with CsA as without.
Recently it has been shown that the response of rabbits to
2 doses of mouse monoclonal antibodies could be completely
suppressed by CsA (Ledermann et al., 1988).
Borel et al. (1977) demonstrated that optimal immuno-
suppression was achieved by maximum doses of CsA at the
time of immunisation. The dose of CsA given was the
maximum amount that has previously been tolerated in
patients. However, an eventual escape from immuno-
suppression occurred in spite of starting CsA 2 days before
the antibody administration to ensure high concentrations of
CsA at the time of antigen challenge.
It is possible that the small quantities of 1311-A5B7
remaining after the completion of CsA therapy led to late
immunisation. At this time the blood concentration of
antibody, projected from the clearance curve, was
15ngml- '. Alternatively, the immune system may have been
primed before exposure to 1311-A5B7. Whilst this can occur
following diagnostic doses of radiolabelled antibody for
tumour localisation (Pimm et al., 1983), most patients who
have pre-existing HAMA have no history of exposure to
mouse immunoglobulins (Shawler et al., 1985; Schroff et al.,
1985). These pre-existing HAMA, at least of the IgM class,
have been shown to be rheumatoid factors that cross react
with murine IgG (Courtenay-Luck et al., 1987). Future
studies will investigate whether continuous therapy at lower
doses of CSA will give more prolonged suppression of
HAMA production.
One additional patient studied had raised HAMA levels
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before therapy and CsA failed to prevent an increase in
HAMA levels before the second dose of antibody. This is in
keeping with the expected failure of CsA to suppress the
secondary immune response (Lindsey et al., 1982). Although
it has been suggested that HAMA formation may result
from intradermal testing with antibody it could not account
for the differences in HAMA levels seen in this study since
all patients had the same intradermal testing.
CsA did not prevent the anti-idiotypic response from
occurring in the patients who eventually escaped immuno-
suppression. An anti-idiotypic antibody was seen as a com-
ponent of pre-existing anti-mouse antibody in two patients;
one who had less than 5/,tgml-1 HAMA and the other with
raised pre-existing antibody (data not shown). It is therefore
unlikely that the combination of CsA and Fab fragments,
which are less immunogenic than intact antibody (Carras-
quillo et al., 1984) will prevent the anti-idiotypic response.
Hybrid antibodies containing a mouse variable region and
human constant region may be less immunogenic but the
potential for an anti-idiotypic response would still appear to
exist.
The anti T cell antibody, OKT3 has not succeeded in
preventing HAMA formation (Jaffers et al., 1986). Immuno-
suppression with large doses of cyclophosphamide has
reduced the incidence of HAMA (Thistlewaite et al., 1986).
However, this is likely to lead to haematological toxicity which
might compromise repeated therapy with immunoconjugates.
Further reasons why CsA appears preferable to other means
of suppressing HAMA and the case for ultracentrifugation
of antibody are discussed in the accompanying paper (Leder-
mann et al., 1988).
Concern that immunosuppression with CsA might acceler-
ate tumour growth was not supported by the preliminary
data here. Although tumour responses were not seen by
WHO criteria, patients were necessarily at a late stage of
disease with large tumours and antibody localisation is likely
to be more efficient when tumours are small (Pedley et al.,
1987). Tumour responses in other studies (Order et al., 1985,
Lenhard et al., 1985, Spitler et al., 1987, Pectasides et al.,
1986) could probably be augmented if therapy could be
repeated. Also, dual phase systems promise to have a much
higher therapeutic ratio than has been attained to date. In
these the therapeutic agent is given after the antitumour
antibody and localises to antibody already on the tumour
(Raso et al., 1982) or is activated at the tumour site by an
enzyme linked to antibody (Bagshawe, 1987). The ability to
give repeated therapy provided by CsA is likely to improve
the results of these approaches to cancer therapy.
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